We have read with great interest the updated American Urological Association (AUA) guidelines for the management of benign prostatic hyperplasia (BPH), which now include prostatic artery embolization (PAE) as a treatment alternative for symptomatic patients [
1]. This is the culmination of a 15-year effort, beginning with animal studies and early human trials of PAE from 2008 to 2011 [
2,
3], further informed by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and Society of Interventional Radiology (SIR) consensus statements in 2014 and 2019 [
4,
5], and ultimately driven by consistently positive results in large cohort studies, randomized controlled trials, and sham studies of PAE [
6‐
9]. …